In this opinion piece Alloplex’s Founder and CEO, Dr. Frank Borriello, comments on an article that appeared in Endpoints on the topic of technology’s ability to revolutionize medicine.

“I could not agree more with George Yancopoulos of Regeneron, that the hype around AI has outpaced reality by a large margin. The fact that the terms machine learning, which has been deployed for years, and artificial intelligence are getting conflated does little to advance the discussion,” comments Dr. Borriello.

“What is clear is that AI relies on quality data training sets from which to extrapolate patterns and thus make predictions. To the extent that AI requires large training sets, and the available training sets are inadequate, the successful deployment of AI may be delayed.”

Here’s a brief summary, the link to the full article in Endpoints is available in the shared post.

California voters approved a $3 billion investment in stem cell research over 20 years ago. This investment was driven by excitement about the technology’s potential to revolutionize medicine. However, the actual medical breakthroughs resulting from this investment have been limited.

In the article, ‘Billionnaire biotech firebrand’, George Yancopoulos – Regeneron’s chief scientific officer – draws a parallel between this situation and the current overhype surrounding Artificial Intelligence. He believes both stem cell research and AI, while powerful tools, often suffer from unrealistic expectations.